The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials
- PMID: 20698807
- PMCID: PMC3513399
- DOI: 10.3109/17482968.2010.502940
The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials
Abstract
Abstract Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Further understanding of these factors will lead to improvements in patient stratification, and in the design of future clinical trials.
Conflict of interest statement
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
References
-
- Beghi E, Logroscino G, Chiò A, Hardiman O, Mitchell D, Swingler R. The epidemiology of ALS and the role of population based registries. BBA. 2006;1762:1150–7. - PubMed
-
- Annegers JF, Appel S, Lee JR, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985–1988. Arch Neurol. 1991;48:589–93. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical